Skip to main content
. 2021 Aug 27;11:103–111. doi: 10.1016/j.ibneur.2021.08.003

Fig. 2.

Fig. 2

Network maps of eligible comparisons of the primary outcomes of efficacy (annualized relapse rate) and safety (serious adverse events). The thickness of lines represents the number of studies in each comparison.